Clinical Trials
14 trialsNCT01445288 2026-05-29
Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Completed
NCT03251989 2026-05-29
Rare CNS Tumors Outcomes &Risk
National Institutes of Health Clinical Center (CC)
Completed
NCT04859543 2026-05-01
PPROSPERITIT
Masaryk University
Phase NA Completed
NCT03213678 2026-04-21
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT03213665 2026-04-13
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT06676306 2026-04-01
Patient and Caregiver Priorities in Neuro-oncology Care
Mayo Clinic
Completed
NCT04773782 2026-01-13
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation
Phase 1/2 Completed
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT03638167 2025-12-17
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Seattle Children's Hospital
Phase 1 Completed
NCT01180881 2025-11-10
Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment
Massachusetts General Hospital
Completed
NCT02684838 2025-11-10
VIGILANT
Arbor Pharmaceuticals, Inc.
Completed
NCT05270707 2025-09-24
HyperArc Registry Study
Varian, a Siemens Healthineers Company
Completed
NCT06150547 2025-08-12
A Study of Metabolic Agents Following Brain Radiation
Mayo Clinic
Completed
NCT01931098 2025-08-11
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed